I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ESMO BC 2023

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Jun 26 / Roche
PI3King the right treatment for every patient with HR+ breast cancer
Watch Prof. Sibylle Loibl and Dr Dejan Juric share their expert review and opinions on how therapies targeting the PI3K/AKT pathway can be used to further personalise and optimise the treatment of patients with HR+ breast cancer.

Sign up or login to unlock the full suite of MEDICALLY features

May 12 / Roche and Genentech
Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs. trastuzumab (H) in patients with HER2-positive (+) residual invasive breast cancer after neoadjuvant treatment (NAT)
This exploratory biomarker analysis aimed to identify prognostic gene sets in the adjuvant trastuzumab emtansine and trastusumab arms of the Phase III KATHERINE study (NCT01772472) using differential gene expression and non-negative matrix factorisation clustering.

Sign up or login to unlock the full suite of MEDICALLY features

May 12 / Roche and Genentech
Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab▼ for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study
Phrancesca was a patient preference study in which oatients received pertuzumab + trastuzumab▼ intravenously for 3 cycles followed by fized-dose combination for 3 cycles, or vice-cersa.. Subsequent treatment, up to 18 cycles, was according to patients' preferred route of administration. This poster reports 3-years efficacy and safety.
05:29 PM